ArticleFrontiers in immunology2026
Humoral immune responses to hyaluronan oligosaccharides in patients undergoing prosthetic valve surgery.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Bioprosthetic heart valves (BHVs) are widely used in cardiac surgery but are limited by structural valve deterioration (SVD). The Translink study showed that immune responses to xenogeneic glycans contribute to SVD. Hyaluronan (HA), a glycosaminoglycan with size-dependent biological functions, has been implicated in inflammation, xenoreactivity, and valve calcification. This study investigated humoral immune responses to HA oligosaccharides in a subgroup of the Translink cohort. Patients and methods: Serum samples from 258 BHV recipients and 78 cardiac surgery controls were analyzed by ELISA, and a representative subset was further profiled using a printed glycan array (PGA). BHV recipients were classified with clinically significant SVD (A), as Results: All subjects exhibited measurable baseline anti-HA IgG and IgM antibodies. ELISA revealed a fragment-length dependence, with the shortest fragment, HA2, showing the highest antibody binding, and progressively lower reactivity with longer oligomers. Following Conclusions: Anti-HA antibodies are constitutively present in humans, undergo transient amplification after cardiac surgery, regardless of prosthesis type, and display marked fragment-length specificity. Short HA2 fragments predominate in ELISA responses, whereas intermediate-length oligomers, such as HA34, emerge as conserved, immunodominant targets in PGA. These findings extend the Translink paradigm from xenogeneic to matrix-derived glycan immunity and identify anti-HA antibodies as potential biomarkers of postoperative inflammation and tissue remodeling, which could be relevant to SVD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.